|
| 38095433 | Erratum for Gebo et al., "Early antibody treatment, inflammation, and risk of post-COVID conditions". | mBio | 2024 |
| 38009954 | COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial. | Microbiol Spectr | 2024 |
| 38095433 | Erratum for Gebo et al., "Early antibody treatment, inflammation, and risk of post-COVID conditions". | mBio | 2024 |
| 37961119 | Early antiviral CD4 and CD8 T cell responses and antibodies are associated with upper respiratory tract clearance of SARS-CoV-2. | bioRxiv | 2024 |
| 37861675 | Hepatitis B virus clinical and virologic characteristics in an HIV perinatal transmission study in sub-Saharan Africa. | AIDS | 2024 |
| 37861675 | Hepatitis B virus clinical and virologic characteristics in an HIV perinatal transmission study in sub-Saharan Africa. | AIDS | 2024 |
| 37961119 | Early antiviral CD4 and CD8 T cell responses and antibodies are associated with upper respiratory tract clearance of SARS-CoV-2. | bioRxiv | 2024 |
| 38009954 | COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial. | Microbiol Spectr | 2024 |
| 35975297 | Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV). | Clin Infect Dis | 2023 |
| 35975297 | Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV). | Clin Infect Dis | 2023 |
| 36101518 | Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States. | Clin Infect Dis | 2023 |
| 36170749 | Self-reported Antiretroviral Adherence: Association With Maternal Viral Load Suppression in Postpartum Women Living With HIV-1 From Promoting Maternal and Infant Survival Everywhere, a Randomized Controlled Trial in Sub-Saharan Africa and India. | J Acquir Immune Defic Syndr | 2023 |
| 35579509 | Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial. | Clin Infect Dis | 2023 |
| 36210483 | Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019. | Clin Infect Dis | 2023 |
| 38045374 | SARS-CoV-2 monoclonal antibody treatment followed by vaccination shifts human memory B cell epitope recognition suggesting antibody feedback. | bioRxiv | 2023 |
| 37745410 | Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody. | bioRxiv | 2023 |
| 37659419 | Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study. | Lancet Microbe | 2023 |
| 37650237 | Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial. | J Infect Dis | 2023 |
| 37650236 | Long COVID After Bamlanivimab Treatment. | J Infect Dis | 2023 |
| 37650234 | Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial. | J Infect Dis | 2023 |
| 37650232 | Immune Status and SARS-CoV-2 Viral Dynamics. | J Infect Dis | 2023 |
| 37650233 | Variant-Specific Viral Kinetics in Acute COVID-19. | J Infect Dis | 2023 |
| 37650231 | ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients. | J Infect Dis | 2023 |
| 37650230 | Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19. | J Infect Dis | 2023 |
| 37724870 | Early antibody treatment, inflammation, and risk of post-COVID conditions. | mBio | 2023 |
| 37713024 | Equitable implementation of lung cancer screening: avoiding its potential to mirror existing inequities among people who use tobacco. | Cancer Causes Control | 2023 |
| 37567204 | Realising long-acting ART as first-line treatment. | Lancet HIV | 2023 |
| 37880481 | Metabolomic profiling of preterm birth in pregnant women living with HIV. | Metabolomics | 2023 |
| 37869406 | Biological and Clinical Implications of the Vascular Endothelial Growth Factor Coreceptor Neuropilin-1 in Human Immunodeficiency Virus. | Open Forum Infect Dis | 2023 |
| 37689805 | REPRESENT recommendations: improving inclusion and trust in cancer early detection research. | Br J Cancer | 2023 |
| 37279602 | One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial. | Clin Infect Dis | 2023 |
| 36966617 | Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV. | EBioMedicine | 2023 |
| 36824860 | Early Treatment, Inflammation and Post-COVID Conditions. | medRxiv | 2023 |
| 37131659 | Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial. | medRxiv | 2023 |
| 37069219 | The importance of appropriate selection of clinical endpoints in outpatient COVID-19 clinical trials. | Commun Med (Lond) | 2023 |
| 37068272 | Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19. | Ann Intern Med | 2023 |
| 37313452 | Community paramedicine in Central Oregon: A promising model to reduce non-urgent emergency department utilization among medically complex Medicaid beneficiaries. | J Am Coll Emerg Physicians Open | 2023 |
| 37125067 | The Community Research Liaison Model: Facilitating community-engaged research. | J Clin Transl Sci | 2023 |
| 36805331 | Effect of host factors and COVID-19 infection on the humoral immune repertoire in treated HIV. | JCI Insight | 2023 |
| 36802755 | Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection. | Ann Intern Med | 2023 |
| 37439633 | Pericoronary Adipose Tissue Density, Inflammation, and Subclinical Coronary Artery Disease Among People With HIV in the REPRIEVE Cohort. | Clin Infect Dis | 2023 |
| 36998633 | Coronary Artery Plaque Composition and Severity Relate to the Inflammasome in People With Treated Human Immunodeficiency Virus. | Open Forum Infect Dis | 2023 |
| 36935656 | Represent: A community engagement roadmap to improve participant representation in cancer early detection research: An Oregon case study. | Front Public Health | 2023 |
| 36793080 | Experiences with telemedicine for HIV care in two federally qualified health centers in Los Angeles: a qualitative study. | BMC Health Serv Res | 2023 |
| 37167996 | Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial. | Lancet HIV | 2023 |
| 36661240 | Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19. | J Infect Dis | 2023 |
| 37535953 | Comparison of Antiretroviral Therapies in Pregnant Women Living With Human Immunodeficiency Virus and Hepatitis B Virus: A Randomized Controlled Trial. | Obstet Gynecol | 2023 |
| 37534607 | Transfusion reactions associated with COVID-19 convalescent plasma in outpatient clinical trials. | Transfusion | 2023 |
| 37486775 | Pitavastatin to Prevent Cardiovascular Disease in HIV Infection. | N Engl J Med | 2023 |
| 37099295 | Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials. | JAMA Netw Open | 2023 |